Previous 10 | Next 10 |
VistaGen Therapeutics (NASDAQ: VTGN ): FY GAAP EPS of -$0.50. More news on: VistaGen Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
SOUTH SAN FRANCISCO, Calif. , June 29, 2020 /PRNewswire/ -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (CNS) diseases and disorders with high unmet nee...
Deals and Financings VistaGen (VTGN) of South San Francisco out-licensed China/Southeast Asia rights for a novel anxiety treatment to EverInsight Therapeutics, a China in-licensing company, in a $177 million agreement. VistaGen's PH94B is a rapid-onset neurosteroid drug candidate for mul...
SOUTH SAN FRANCISCO, Calif. and SHANGHAI , June 25, 2020 /PRNewswire/ -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (CNS) diseases and disorders with...
VistaGen Therapeutics ( VTGN ) will collaborate with Nuformix plc to develop novel cocrystal-based formulations of VTGN central nervous system (CNS) candidates. More news on: VistaGen Therapeutics, Inc., Healthcare stocks news, Read more ...
SOUTH SAN FRANCISCO, Calif. , May 27, 2020 /PRNewswire/ -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (CNS) diseases and disorders with high unmet need...
VistaGen Therapeutics ( OTC:VTGN ) has submitted its proposed protocol to the FDA for a Phase 2A study of PH94B, its investigational anti-anxiety drug, for treatment of adjustment disorder with anxiety (AjDA) related to the COVID-19. More news on: VistaGen Therapeutics, Inc., H...
SOUTH SAN FRANCISCO, Calif. , May 18, 2020 /PRNewswire/ -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for anxiety and depression, as well as certain central nervous system (CNS) diseases and disorders with hi...
VistaGen Therapeutics ( OTC:VTGN ) has filed a prospectus for a 13.1M common shares from stockholders. More news on: VistaGen Therapeutics, Inc., Healthcare stocks news, , Read more ...
Thinly traded nano cap VistaGen Therapeutics ( OTC:VTGN +7.3% ) is up in early trade on double normal volume in reaction to its plan to expand development of PH94B, a rapid-onset neuroactive nasal spray, to include the potential treatment of adjustment disorder related to the stress of t...
News, Short Squeeze, Breakout and More Instantly...
VistaGen Therapeutics Inc. Company Name:
VTGN Stock Symbol:
NASDAQ Market:
VistaGen Therapeutics Inc. Website:
Vistagen Therapeutics (NASDAQ: VTGN ), a clinical-stage, neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, has received multiple new patent...
Vistagen (Nasdaq: VTGN), a clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, today announced the broadening of its global in...
Vistagen (NASDAQ: VTGN) , a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that it has been recognized by Mental Health America (“MHA”) for its dedication to pr...